Literature DB >> 7690411

Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

I M Fernández1, A Snijders, B J Benaissa-Trouw, M Harmsen, H Snippe, C A Kraaijeveld.   

Abstract

The antibody response to a previously defined B-cell epitope of Semliki Forest virus (SFV) was investigated in male BALB/c (H-2d) mice. The B-cell epitope, located at amino acid positions 240 to 255 of the E2 protein, was linked to an H-2d-restricted T-helper cell epitope of SFV located at positions 137 to 151 of the E2 protein. Colinearly synthesized peptides, of either T-B or B-T polarity, mixed with different adjuvants (the nonionic block copolymer L 180.5, a water-oil-water [W/O/W] emulsion of L 180.5, Montanide, and Q VAC) were used for immunization. Generally, after one booster immunization, high serum antibody titers were measured against either peptide. With Q VAC and W/O/W L 180.5 as adjuvants, the titers of SFV-reactive (nonneutralizing) antibodies were consistently much higher after immunization with the T-B peptide than with the B-T peptide, which was reflected in a higher vaccine efficacy. With these two adjuvants, the survival ratio in T-B peptide-immunized mice was 82%, compared with 8% in B-T peptide-immunized mice. Intermediate results were obtained with the adjuvant Montanide. L 180.5 alone was ineffective in this study. All immunoglobulin G (IgG) isotypes were induced with either adjuvant, but Q VAC was clearly the most effective in inducing IgG2a and IgG2b isotypes with the T-B peptide as the antigen. Subsequently, monoclonal antibodies (MAbs) of IgM, IgG1, IgG2a, IgG2b, and IgG3 subclasses were prepared against the B-cell epitope. These nonneutralizing but SFV-reactive MAbs protected 40 to 80% of mice against a lethal challenge with SFV. Control mice all died. The availability of those antipeptide MAbs allowed competition binding assays with a previously characterized panel of E2-specific MAbs. Binding of enzyme-labeled antipeptide MAbs was very effectively inhibited by two strongly SFV-neutralizing mutually competitive MAbs, suggesting that the linear B-cell epitope (amino acids 240 to 255) is associated with a major neutralization site of SFV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690411      PMCID: PMC238002     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Prophylaxis and therapy of virulent encephalomyocarditis virus infection in mice by monoclonal antibodies. Brief report.

Authors:  F Vlaspolder; C A Kraaijeveld; R van Buuren; M Harmsen; B J Benaissa-Trouw; H Snippe
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  Location of a major antigenic site involved in Ross River virus neutralization.

Authors:  S Vrati; C A Fernon; L Dalgarno; R C Weir
Journal:  Virology       Date:  1988-02       Impact factor: 3.616

3.  Peroxidase-labeled antibody. A new method of conjugation.

Authors:  P K Nakane; A Kawaoi
Journal:  J Histochem Cytochem       Date:  1974-12       Impact factor: 2.479

Review 4.  Adjuvants.

Authors:  K Dalsgaard
Journal:  Vet Immunol Immunopathol       Date:  1987-12       Impact factor: 2.046

5.  Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.

Authors:  A L Schmaljohn; E D Johnson; J M Dalrymple; G A Cole
Journal:  Nature       Date:  1982-05-06       Impact factor: 49.962

6.  Nucleotide sequence of cdna coding for Semliki Forest virus membrane glycoproteins.

Authors:  H Garoff; A M Frischauf; K Simons; H Lehrach; H Delius
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

7.  Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus.

Authors:  W A Boere; B J Benaissa-Trouw; T Harmsen; T Erich; C A Kraaijeveld; H Snippe
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

8.  Adjuvants influence the immunoglobin subclass distribution of immune responses in vivo.

Authors:  L Hadjipetrou-Kourounakis; E Möller
Journal:  Scand J Immunol       Date:  1984-03       Impact factor: 3.487

Review 9.  An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.

Authors:  A C Allison; N E Byars
Journal:  J Immunol Methods       Date:  1986-12-24       Impact factor: 2.303

10.  Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities.

Authors:  W A Boere; T Harmsen; J Vinjé; B J Benaissa-Trouw; C A Kraaijeveld; H Snippe
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

View more
  5 in total

1.  Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Authors:  H Plotnicky-Gilquin; L Goetsch; T Huss; T Champion; A Beck; J F Haeuw; T N Nguyen; J Y Bonnefoy; N Corvaïa; U F Power
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  The potential of immunization with synthetic peptides to overcome the immunosuppressive effect of maternal anti-measles virus antibodies in young mice.

Authors:  O E Obeid; M W Steward
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

Review 3.  Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Authors:  E AlonsoDeVelasco; A F Verheul; J Verhoef; H Snippe
Journal:  Microbiol Rev       Date:  1995-12

4.  Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.

Authors:  Ivette Caro-Aguilar; Alexandra Rodríguez; J Mauricio Calvo-Calle; Fanny Guzmán; Patricia De la Vega; Manuel Elkin Patarroyo; Mary R Galinski; Alberto Moreno
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

5.  Bcipep: a database of B-cell epitopes.

Authors:  Sudipto Saha; Manoj Bhasin; Gajendra P S Raghava
Journal:  BMC Genomics       Date:  2005-05-29       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.